AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration - though much of what it is ...

AstraZeneca has announced a US$50 billion investment in the United States by 2030, building on America’s global leadership in ...

British pharmaceuticals giant AstraZeneca has revealed it plans to invest $50 billion (£37 billion) in America over the next ...

AstraZeneca Plc. announced on Monday that it plans to invest $50 billion in the U.S. by 2030, with a focus on expanding drug ...

AstraZeneca ( AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

The company said the Virginia facility "would be AstraZeneca’s largest single manufacturing investment in the world." The ...

Virginia facility investment will be AstraZeneca’s largest yet. Maryland, Massachusetts, California, Indiana, Texas projects ...

AstraZeneca announces $50B US investment by 2030, creating thousands of jobs and building its largest drug manufacturing facility in Virginia.

AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small ...

Research news of note last week included US biotech Crinetics Pharmaceuticals releasing new Phase III data on its acromegaly drug candidate Palsonify (paltusotine). AstraZeneca announced positive ...

Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.